MaÃ«l Heiblig

List of Publications by Year
in descending order

28 papers	910 citations	759233 12 h-index	526287 27 g-index
29 all docs	29 docs citations	29 times ranked	991 citing authors

#	Article	IF	Citations
1	Further characterization of clinical and laboratory features in VEXAS syndrome: largeâ€scale analysis of a multicentre case series of 116 French patients*. British Journal of Dermatology, 2022, 186, 564-574.	1.5	174
2	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 2018, 24, 1167-1177.	30.7	157
3	Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood, 2021, 137, 3682-3684.	1.4	145
4	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Advances, 2022, 6, 998-1003.	5.2	88
5	Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood, 2022, 140, 927-931.	1.4	86
6	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. British Journal of Haematology, 2022, 196, 969-974.	2.5	85
7	Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives. Leukemia Research, 2014, 38, 1145-1153.	0.8	21
8	Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 477-483.	0.4	18
9	TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016009.	1.3	17
10	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 523-530.	1.8	15
11	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. Cancers, 2019, 11, 570.	3.7	14
12	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.3	12
13	The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert Opinion on Drug Discovery, 2016, 11, 1061-1070.	5.0	9
14	Acute myeloid leukemia in the elderly (age 70 yr or older): longâ€term survivors. European Journal of Haematology, 2017, 98, 134-141.	2.2	9
15	Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Frontiers in Immunology, 2022, 13, 841470.	4.8	9
16	Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: AÂSingle-Center Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S7-S13.	0.4	8
17	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. Expert Review of Hematology, 2020, 13, 619-643.	2.2	7
18	Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2016, 5, 77-90.	1.6	6

#	Article	IF	Citations
19	Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry. Leukemia Research, 2021, 111, 106673.	0.8	6
20	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e211-e218.	0.4	5
21	LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A â€˜REAL-LIFEâ€™ STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020020.	1.3	4
22	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	3.7	4
23	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.7	3
24	Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication. Cancers, 2021, 13, 2272.	3.7	3
25	Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. Leukemia Research, 2019, 76, 29-32.	0.8	2
26	Acute Promyelocytic Leukemia. Cancers, 2020, 12, 3718.	3.7	2
27	Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs, 2022, 27, 169-185.	2.4	1
28	Decitabine for the treatment of adult patients (age â‰¥65 years) with newly diagnosedde novoor secondary acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 305-314.	1.6	0